周五盘前，制药巨头辉瑞（Pfizer）股价大跌5%，引发市场关注。这一跌幅或与公司近期宣布的一项重大收购有关。
据报道，辉瑞以近100亿美元的高价成功收购了成立仅三年的减肥药新贵公司Metsera。这家源自帝国理工学院研究团队的公司，凭借其在肥胖及相关代谢疾病治疗药物领域的创新技术，迅速成为市场焦点。对辉瑞而言，这次收购是一次战略性的补位，旨在快速进入快速增长的减重药市场。
然而，如此高昂的收购价格似乎引发了投资者的担忧。特别是考虑到辉瑞自身在减重药研发方面屡屡受挫，其管线内的GLP-1减重药Danuglipron因安全隐患已终止研发。市场可能质疑辉瑞是否overpaid，以及能否有效整合Metsera的技术并实现预期收益。这些因素可能是导致辉瑞股价在盘前大幅下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.